Ultragenyx Hits Record Revenue but Faces Critical FDA Deadlines
Event summary
- Ultragenyx reported $214M in Q2 2026 revenue, a company record.
- Crysvita® generated $156M and Dojolvi® $27M in the quarter.
- Reaffirmed 2026 guidance: $730M–$760M total revenue, profitability targeted for 2027.
- Two FDA PDUFA dates loom: DTX401 (August 23) and UX111 (September 19).
- GTX-102 Phase 3 data for Angelman syndrome expected in September/October.
The big picture
Ultragenyx is navigating a pivotal period, balancing near-term revenue growth with high-stakes regulatory decisions. The company’s focus on gene therapies aligns with broader industry trends toward curative treatments for rare diseases, but success hinges on securing FDA approvals and demonstrating sustained profitability.
What we're watching
- Regulatory Approvals
- Whether the FDA will approve DTX401 and UX111 by their PDUFA dates, which would unlock new revenue streams.
- Clinical Data Impact
- How GTX-102 Phase 3 results for Angelman syndrome could reshape the company’s pipeline valuation.
- Cost Management
- The pace at which Ultragenyx can reduce R&D and SG&A expenses to meet its 2027 profitability target.
Related topics